PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PEP-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PEP-010 overview
PEP-010 (DPTC-9h) is under development for the treatment of metastatic solid tumors including triple negative breast cancer, platinum resistant metastatic ovarian cancer and pancreatic ductal adenocarcinoma. The drug candidate is a recombinant peptide (30 amino acids) constituting two sequences, DPT as a penetrating peptide and PEP1 as the interfering active peptide. It acts by targeting protein phosphatase 2A (PP2A). It is developed based on cell penetrating and interfering peptides (CP and IP) technology. It is administered through intravenous route. It was also under development for chronic lymphocytic leukemia (CLL) and lung cancer.
PEP-Therapy overview
PEP-Therapy is a medical biotechnology company that develops targeted therapies for treatment of types of cancers. The company develops cell penetrating and interfering peptides for the intracellular delivery of targeted therapies. Its pipeline products include PEP-010 with a penetrating shuttle to deliver the active peptide into the cell, and an interfering active peptide blocking Caspase-9/PP2A interaction. The company’s product is used for the treatment of triple-negative breast cancer, lung and ovary cancers, and chronic lymphocytic leukemia. It also conducts clinical trials and licenses the novel therapeutic products and companion biomarkers to both pharmaceutical and biotech companies for their development and commercialization. PEP-Therapy is headquartered in Paris, France.
For a complete picture of PEP-010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
